Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Neoangiogenesis is involved in the pathophysiology of multiple myeloma and angiopoietins possibly contribute to myeloma-induced neovascularization. Bortezomib's antineoplastic potential includes an anti-angiogenic effect. We determined serum levels of angiopoietin-1 and angiopoietin-2 with ELISA pre- and post-bortezomib administration in 35 patients with relapsed/refractory multiple myeloma. Pre-bortezomib, serum angiopoietin-1 levels did not differ in patients and in healthy individuals, while serum angiopoietin-2 levels were elevated. Corresponding serum angiopoietin-1/angiopoietin-2 ratio was reduced in patients compared with controls. After treatment, serum angiopoietin-1 levels increased, while serum angiopoietin-2 levels decreased, therefore the angiopoietin-1/angiopoietin-2 ratio increased and normalized. This increase was significant in patients who responded to treatment. In conclusion, angiopoietin-1/angiopoietin-2 ratio normalization reflected response to bortezomib.
Anargyrou
Konstantinos
K
Department of Haematology, 251 General Air Force Hospital, Athens, Greece.
Terpos
Evangelos
E
Vassilakopoulos
Theodoros P
TP
Pouli
Anastasia
A
Sachanas
Sotirios
S
Tzenou
Tatiana
T
Masouridis
Stavroula
S
Christoulas
Dimitrios
D
Angelopoulou
Maria K
MK
Dimitriadou
Evangelia M
EM
Kalpadakis
Christina
C
Tsionos
Konstantinos
K
Panayiotidis
Panayiotis
P
Dimopoulos
Meletios A
MA
Pangalis
Gerassimos A
GA
Kyrtsonis
Marie-Christine
MC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D042683:Angiopoietin-1 / Q000097:blood*; D042702:Angiopoietin-2 / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001853:Bone Marrow / Q000098:blood supply; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D009363:Neoplasm Proteins / Q000097:blood* / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D042787:Receptor, TIE-2 / Q000502:physiology; D016879:Salvage Therapy; D016896:Treatment Outcome
C467630:ANGPT1 protein, human; D042683:Angiopoietin-1; D042702:Angiopoietin-2; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001897:Boronic Acids; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D042787:Receptor, TIE-2